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Abstract
 Objective—The Cancer Genome Atlas (TCGA) identified four integrated clusters for 
endometrial cancer (EC): POLE, MSI, CNL and CNH. We evaluated differences in gene 
expression profiles of obese and non-obese women with EC and examined the association of body 
mass index (BMI) within the clusters identified in TCGA.
 Methods—TCGA RNAseq data was used to identify genes related to increasing BMI among 
ECs. The POLE, MSI and CNL clusters were composed mostly of endometrioid EC. Patient BMI 
was compared between these three clusters with one-way ANOVA. Association between gene 
expression and BMI was also assessed while adjusting for confounding effects of potential 
confounding factors. p-values testing the association between gene expression and BMI were 
adjusted for multiple hypothesis testing over the 20,531 genes considered.
 Results—Mean BMI was statistically different between the ECs in the CNL (35.8) versus 
POLE (29.8) cluster (p=0.006) and approached significance for the MSI (33.0) versus CNL (35.8) 
cluster (p=0.05). 181 genes were significantly up- or down-regulated with increasing BMI in 
endometrioid EC (q-value<0.01), including LPL, IRS-1, IGFBP4, IGFBP7 and the progesterone 
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receptor. DAVID functional annotation analysis revealed significant enrichment in "cell cycle" 
(adjusted p-value=1.5E-5) and "DNA metabolic processes" (adjusted p-value=1E-3) for the 
identified genes.
 Conclusions—Obesity related genes were found to be upregulated with increasing BMI 
among endometrioid ECs. Patients with POLE tumors have the lowest median BMI when 
compared to MSI and CNL. Given the heterogeneity amongst endometrioid EC, consideration 
should be giving to abandoning the Type I and II classification of EC tumors.
 INTRODUCTION
Obesity has been linked to increased risk of many cancers, including breast, colon and 
endometrial, among others [1]. Currently, new cancer cases are in the order of 1.6 million 
annually with over half a million cancer deaths per year, and nearly one in five are estimated 
to be due to obesity [1, 2]. It is postulated that elevations in insulin, glucose, insulin growth 
factor-1 (IGF-1), adipokines and cytokines resulting from over-nutrition in obese patients 
may provide abundant nutrients and growth factors to cancer cells, creating the ideal 
environment for tumor initiation and promotion [3].
Endometrial cancer (EC) is the most common gynecologic malignancy in the United States, 
accounting for 52,360 cases and over 8,500 deaths a year [2]. Traditionally, EC has been 
subdivided into Type I and Type II categories based on clinical and histologic differences. 
Type I cases comprise the majority of the cases and typically arise in a setting of unopposed 
estrogenic states such as obesity. These tumors tend to be well-differentiated, of 
endometrioid histology, diagnosed at early stages, and associated with good prognosis. 
Meanwhile, Type II ECs have classically been presumed to be estrogen independent, poorly 
differentiated, frequently of advanced stage, and associated with worse prognosis. The 
majority of Type II ECs consist of serous histology tumors [4]. Recent genomic 
characterization of EC through the TCGA project classified EC into four integrated clusters: 
POLE ultramutated (POLE), microsatellite instability hypermutated (MSI), copy-number 
low (CNL) and copy-number high (CNH). The POLE, MSI and CNL clusters were 
composed mostly of endometrioid histology tumors, while most serous histology tumors 
were found in the CNH cluster [5]. Women with POLE tumors had the best progression free 
survival (PFS), while women with CNH tumors had the worst PFS [5].
Given the rise in prevalence of obesity and its association with EC, it is imperative to 
investigate obesity as a modifiable risk factor that may reduce risk and lead to prevention 
and/or improved patient outcomes for this disease. We hypothesize that the metabolic 
consequences of obesity may be crucial in the development of EC, resulting in biologically 
distinct cancers than those arising in normal weight women, which could alter treatment 
approaches. Thus, we sought to assess differences in the gene expression profiles of obese 
and non-obese women with EC and to examine the association of BMI with the integrated 
clusters identified in the TCGA project.
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 METHODS
From the TCGA database, we collected expression measurements for 20,531 genes 
(IlluminaGA RNA-seq level 3 data) for differential gene expression analysis among the EC 
samples. Detailed information of the data processing, quality control and normalization can 
be found on the TCGA open access download directories (https://tcga-data.nci.nih.gov/tcga/
tcgaDownload.jsp). The RNA-seq gene expression level 3 data utilized in this study were 
TCGA normalized gene read counts, pre-corrected such that the 75th percentile of each 
patient’s set of gene expression measurements were normalized to a value of 1000.
We identified differentially expressed genes with respect to BMI while adjusting for 
potential confounders via multiple linear regression. Specifically, for a single gene we 
modeled the log of the observed normalized read count from each subject with respect to the 
following predictors: BMI, clinical stage, grade, age, race, residual tumor, five principal 
component score variables (PCs) and subject-specific RNA-seq normalization factor. The 
PCs were computed from the gene expression data to control for potential batch effects in 
the expression data. A value of 1 was added to each sample’s normalized read count value to 
avoid taking the log of a zero count. From our fitted multiple linear regression model for a 
given gene, we then tested the association between BMI and log transformed normalized 
gene read count via the Wald Test. Because we performed this hypothesis test for each of 
20,531 genes in our dataset, the Benjamini–Hochberg procedure was applied to control for 
False Discovery Rates (FDR) [6] and to address multiple testing issues. The p-values that 
were adjusted for FDR using the Benjamini–Hochberg procedure are referred to as adjusted 
p-values, and a threshold of adjusted p-values < 0.01 was used to report the significant 
results to reduce the number of false positives. The genes with the adjusted p-values < 0.01 
were considered as significantly associated with BMI status; functional clustering analysis 
was conducted on those genes using the website of The Database for Annotation, 
Visualization and Integrated Discovery (DAVID) [7, 8]. In addition, hierarchical clustering 
analysis was applied to generate a representative heatmap using R statistical software. One-
way ANOVA was used to detect significant differences in BMI among the different clusters. 
Student’s t-test was used to compare BMI among the different clusters of samples in a 
pairwise manner. Cox proportional hazards regression was utilized to compare survival 
between obese and non-obese patients.
Given the strong association between obesity and endometrioid ECs, in addition to the 
observation that three of the four integrated clusters (i.e. POLE, MSI, and CNL) were 
composed mostly of endometrioid histology [5], we limited our analysis to patients with 
endometrioid histology and excluded patients with serous and mixed histologies. Mean 
BMIs were compared amongst the POLE, MSI and CNL sub-types using Spearman’s 
Correlation.
 RESULTS
Table 1 summarizes the demographics between the EC tumors from non-obese (BMI < 30) 
and obese women (BMI ≥ 30). There were no significant differences in the demographics 
between the EC tumors from non-obese (BMI < 30) and obese women (BMI ≥ 30) (Table 1), 
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except for age being younger in the obese group. The mean age of the obese group was 60.8 
years versus 64.5 years in the non-obese group. Table 2 summarizes the number of deaths 
and median overall survival in months for obese and non-obese patients. We foud that obese 
women had lower median survival compared to non-obese women (332.5 days versus 582.0 
days); however, there was no significant difference in overall survival between groups 
(p=0.18, Hazard Ratio = 1.9), most likely driven by the small number of deaths overall in 
our set of patients.
Of the EC clusters, POLE patients had a mean BMI of 29.8 (non-obese, but overweight), 
MSI had a mean BMI of 33.0 (obesity I classification), while CNL patients had a mean BMI 
of 35.8 (obesity II classification). CNH patients, comprised mostly of serous as opposed to 
endometriod histology tumors, had a BMI of 32.2 (obesity 1 classification). BMI was found 
to be statistically different between the ECs in the CNL (mean 35.8) versus POLE (mean 
29.8) cluster (p=0.006) and approached statistical significance for the MSI (mean 33.0) 
versus CNL (mean 35.8) cluster (p=0.05). As illustrated in Figure 1, women with POLE 
tumors had the lowest median BMI. POLE tumors have been previously found to have 
significantly better PFS than MSI, CNL and CNH tumors [5].
To determine if gene expression of tumors was regulated by BMI, RNA-seq and pathway 
analysis was undertaken. The list of genes was similar regardless of whether BMI was 
treated as a continuous variable or dichotomized into the categories of non-obese (BMI < 
30) versus obese (BMI ≥ 30); therefore, data is presented for BMI as a continuous variable. 
A total of 214 genes were significantly associated with BMI. 161 were up-regulated and 53 
were down-regulated with BMI (BMI < 30 versus BMI ≥ 30) (adjusted p-values< 0.01) 
(Appendix 1). Many of the genes identified have metabolically relevant activities related to 
obesity, including lipoprotein lipase (4.0-fold elevated expression in tumors from obese 
women over non-obese women), insulin receptor substrate 1 (5.1-fold), insulin-like growth 
factor binding protein 7 (4.7-fold), insulin-like growth factor binding protein 4 (4.4-fold) and 
the progesterone receptor (5.0-fold). DAVID functional annotation analysis revealed 
significant enrichment in "cell cycle" (adjusted p-value = 1.5E-5) and "DNA metabolic 
processes" (adjusted p-value = 1E-3). Other pathways or annotations did not have significant 
p-values after multiple testing correction.
Hierarchical clustering was applied by using the 181 genes with a q value of <0.01, but the 
obtained heatmap did not show a sufficiently clear pattern. Therefore, a more stringent q 
value cut-off of 0.001 was applied to select genes for hierarchical clustering. The generated 
dendrogram identified three clusters for both individuals and genes (Figure 2). The three 
clusters were characterized by the proportions of obese and non-obese individuals. 
Specifically, the three clusters were named as “majority obese” because 69% of the patients 
were obese, “majority non-obese” contained 33% obese, and “mixed obese and non-obese” 
contained 59% obese patients. In addition, functional clustering analysis was conducted for 
the three clusters of genes. The first cluster of genes had significant enrichment in "cilium" 
(adjusted p-value = 3.4E-8) and "microtubule" (adjusted p-value = 5.1E-4) by DAVID 
functional annotation analysis. The second cluster of genes had significant enrichment in 
"cell cycle" (adjusted p-value = 4.7E-28) and "DNA metabolic processes" (adjusted p-value 
= 9E-14). The third cluster of genes did not show any functional enrichment by DAVID 
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analysis. A summary of the genes in gene cluster 1 (cilium & microtubule cluster), 2 (cell 
cycle & DNA metabolic processes cluster) and 3 (no functional enrichment cluster) can be 
found in Table 3.
 DISCUSSION
Obesity is a well-established risk factor for EC, with each increase in BMI of 5 kg/m2 
accounting for a significant increased risk of developing EC (RR 1.59; 95% CI 1.50–1.68) 
[9]. Higher BMI has also been associated with the development of EC before age 45 [10]. In 
addition, in patients with endometrial adenocarcinoma, severe obesity (BMI > 40 kg/m2) 
carries a 6.25-fold increased risk of death compared to normal weight women (BMI 18.5 – 
24.9) [1]. Obesity is a high-energy, pro-inflammatory condition that culminates in increased 
growth factor signaling via the insulin/IGF-1 axis, as well as a nutrient-saturated 
environment via increased glucose (and other nutrients), ultimately aiding in the 
development of endometrial cancer [3]. Therefore, obesity may create a unique environment 
that can be exploited by a therapeutic approach as a strategy to improve EC outcomes.
To better understand the molecular basis for EC tumorigenesis in obese women, differential 
gene expression was compared between endometrial tumors of obese versus non-obese 
patients, using the TCGA database. Several genes were significantly up-regulated with BMI 
that are known to play important roles in EC pathogenesis. Some of these somatic 
aberrations included lipoprotein lipase (LPL); insulin receptor substrate 1 (IRS-1); insulin-
like growth factor binding protein 7 (IGFBP7); insulin-like growth factor binding protein 4 
(IGFBP4); and the progesterone receptor (PGR). DAVID analysis also identified 
proliferative pathways including cell cycle and DNA metabolic processes. How obesity 
regulated genes may be associated with EC is discussed as follows.
 Lipoprotein lipase (LPL)
The expression of LPL was increased by 4-fold in the endometrial cancers from obese as 
compared to non-obese patients. LPL is involved in triglycerides hydrolysis and generation 
of fatty acids [11]. LPL appears to be upregulated in the presence of elevated glucose and 
certain fatty acids [11], as it is commonly the case in obese patients. Non-catalytic functions 
of LPL are carried on the protein C-terminus and include dimerization and bridging between 
lipoproteins and cell surface receptors such as heparin sulfate proteoglycans (HSPG) [12]. 
Bridging may involve different cell types, requiring LPL dimerization and HSPG on both 
surfaces [13]. Accordingly, expression of LPL by malignant cells may promote 
tumorigenesis by enabling the cell–stromal interactions that are critical for tumor 
maintenance [13, 14]. In fact, LPL is overexpressed in squamous cell carcinomas of the 
cervix and may be associated with increased tumor aggressiveness, likely secondary to the 
non-catalytic function of LPL [13]. Therefore, overexpression of LPL in the EC of obese 
women may be linked with the poorer outcomes that are associated with this patient 
population. If the increased tumor aggressiveness is in fact related to the non-catalytic C-
terminal domain of LPL, that domain could potentially serve as a therapeutic target.
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 Insulin receptor substrate 1 (IRS-1)
Insulin receptor substrate 1 in endometrial tumors of obese women was increased 5.1-fold 
compared to tumors from non-obese patients. The insulin-like growth factor (IGF) signaling 
pathway is a complex system comprised of hormones, cell-surface receptors, as well as 
circulating and membrane bound IGF-binding proteins (IGFBP). This pathway plays a key 
role in the growth and development of many normal tissues but also plays a major role in the 
link between the metabolic syndrome/obesity and cancer [15]. Cell signaling occurs through 
the interaction of IGF-I, IGF-II and insulin with IGF-IR, IGF-IIR, the insulin receptor (IR) 
and hybrid receptors of IGF and insulin [16]. One of the substrates that interacts with the 
activated IGF-IR is the insulin receptor substrate (IRS)-1, which continues to transmit the 
IGF-IR signal downstream ultimately leading to activation of the type I phosphatidylinositol 
3-kinase (PI3K)/Akt (PKB: protein kinase B), mammalian target of rapamycin (mTOR) 
pathway [17, 18]. Activation of the PI3k/Akt/mTOR pathway leads to cell proliferation and 
inhibition of apoptosis.
Given the close relationship between obesity, hyperinsulinemia, the IGF signaling pathway 
and cancer, it is not surprising that IRS-1 was significantly over-expressed in the majority 
obese group. In general, IRS-1 exhibits increased expression in other malignancies including 
pancreatic, prostatic, and breast cancers [19–21]. However, overexpression of IRS-1 is not 
only a factor in tumorigenesis, but it also appears to increase cellular resistance to 
autophagy-dependent cell death caused by oxidative stress [22]. In addition, IRS-1 has an 
anti-apoptotic function that protects cells from apoptotic cell death [23]. Therefore, the 
significant overexpression of IRS-1 in the obese women may yet serve as another 
explanation for increased risk of developing EC. In addition, the anti-apoptotic and anti-
autophagic functions associated with overexpression may also explain the difference in 
survival in this patient population.
 Insulin-like growth factor binding protein 4 (IGFBP4)
Overexpression of IGFBP4 (4.4-fold) was detected in the obese EC group. Binding of IGF 
to IGFBPs prolongs IGF’s half-life. In addition, through high affinity binding, IGFBP can 
sequester IGFs away from their cell surface receptor, thus modulating IGFs biologic 
functions in target cells [24]. IGFBP4 appears to have IGF-independent anti-tumorigenic 
and anti-angiogenic activity in human glioma cells lines as well as in a glioblastoma 
xenograft model [25]. The anti-angiogenic and anti-tumorigenic inherent activity of IGFBP4 
appears to be associated to the C-terminal domain, while the IGF-binding domain is 
localized to the N-terminus [25]. Whether or not IGFBP4 has similar anti-tumorigenic 
activity in EC is unknown. However, assuming that the IGF-independent activity translates 
to endometrial carcinoma, IGFBP4 could serve as yet another therapeutic target. The fact 
that it appears to be overexpressed in the mostly obese group may likely be a physiologic 
response to the increased circulating levels of insulin and IGF in this patient population. 
Thus, we would postulate that typically the IGF-dependent activity of IGFBP4 is 
dominating. However, if IGFBP4 does in fact block cancer progression in an IGF-
independent fashion, we could potentially use the increased circulating levels to our 
advantage by blocking the IGF binding site and effectively activating the anti-tumorigenic 
and anti-angiogenic protein C-terminus.
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 Insulin-like growth factor binding protein 7 (IGFBP7)
IGFBP7 was upregulated 4.7-fold in obese compared to non-obese patient tumors. Unlike 
IGFBP 1–6, IGFBP7 has a relatively low affinity for IGF-1 while its affinity for insulin is up 
to 500-fold higher [26]. Elevated serum levels of IGFBP7 are linked to insulin resistance and 
Type II diabetes [26, 27]. Therefore, the increased expression of IGFBP7 in the mostly 
obese cohort may be secondary to their increased risk of insulin resistance rather than a 
direct or indirect effect from their tumor physiology. Currenlty, the role of IGFBP7 in EC 
pathogenesis remains poorly understood.
 Progesterone receptor (PGR)
PGR was detected at 5-fold greater levels in obese compared to non-obese tumors. PGR 
expression by uterine cells is stimulated by estrogens via estrogen receptor-α and 
consequently progesterone responsiveness is dependent on the presence of an estrogenic 
drive [28, 29]. As the levels of progesterone increase during the secretory phase, activation 
of the PGR results in inhibition of endometrial proliferation and differentiation into a 
secretory phenotype. However, in hyper-estrogenic states, the effects of progesterone are 
disrupted mainly due to the decreased production of ovarian progesterone due to either 
anovulation or menopause [29]. This abnormal physiology represents one of the major risk 
factors for the development of endometrioid endometrial cancer. Obesity is associated with 
both higher estrogen levels and anovulation, thus explaining the higher expression of PGR in 
the tumors from women in the “mostly obese” group. The understanding that some 
endometrioid ECs have increased PGR expression, has led to the use of progestin agents as a 
therapeutic option for young women with low-grade endometrioid adenocarcinomas 
interested in preserving fertility. However, whether or not higher PGR expression affects 
outcomes remains a topic of debate. A few small studies have failed to show a positive 
relationship between survival and PGR expression [30, 31]. Whereas, a multicenter trial 
found decreased survival in patients with ER and PR receptor loss [32].
 EC clusters from TCGA and relationship to BMI
Integrated genomic, transcriptomic, and proteomic characterization of 373 endometrial 
carcinomas from the TCGA led to classification of these tumors into four clusters based of 
their molecular characteristics [5]. The POLE cluster represented tumors with ultra-high 
mutation rates in the POLE gene, which is involved in nuclear DNA replication and repair. 
The MSI cluster was composed of hyper-mutated tumors with microsatellite instability, as 
well as reduced expression of the DNA mismatch repair gene MLH1, due to methylation of 
its promoter region. The CNL cluster consisted of tumors with lower mutations frequencies 
as well as the majority of microsatellite-stable cancers. Lastly, the CNH cluster primarily 
encompassed serous and many high-grade endometrioid tumors with overall low mutation 
rates but with frequent TP53 mutations. Surprisingly, the POLE cluster, despite having the 
highest mutation rate was associated with the best PFS, followed by MSI and CNL tumors. 
As expected, given the predominance of serous cancers in this cluster, CNH tumors were 
associated with the worst PFS out of the four clusters. Based on our analysis, there appeared 
to be an association between obesity and the EC integrated clusters. Women with CNL 
tumors had the highest BMI whereas women with POLE tumors had the lowest BMI. These 
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findings further suggested that obesity affects tumor biology at the molecular level, and 
ultimately these changes may lead to more aggressive tumors and poorer outcomes.
 Conclusions
Our study is the first to examine the association between BMI and the integrated EC clusters 
identified through analysis of the TCGA data. We demonstrate that increasing BMI was 
associated with metabolically relevant alterations in gene expression among endometrioid 
ECs, including genes related to the insulin/IGF-1 pathway among others. As previously 
reported by TCGA, integrated genomic characterization of endometrial carcinomas found 
POLE tumors to be associated with significantly better progression free survival than any of 
the other clusters [5]. Meanwhile, in our study, patients with POLE tumors had the lowest 
median BMI, suggesting a correlation between BMI and survival of EC integrated clusters. 
Our study had several limitations mainly stemming from the fact that it was a post-hoc 
analysis. Because of this, we were not able to control for other factors such as diabetes, 
insulin and metformin use, which may affect tumor behavior and outcomes.
In conclusion, our findings suggest that the metabolic consequences of obesity may play a 
role in tumor development and resultant tumor biology and aggressiveness. The genetic 
heterogeneity found among Type 1 cancers based on BMI in combination with that 
previously seen among the four integrated EC clusters in TCGA provides further support 
that the classification of endometrial cancers into the categories of Type I and II tumors is 
too simplistic. Lastly, further work is needed focusing on the identification of pathways and 
biomarkers unique to obese women, which could prove useful in the development of 
targeted therapies or diagnostic tools more specific to this high risk patient population and 
obesity-driven ECs.
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Highlights
• Women with POLE endometrial tumors have the lowest average BMI 
when compared to women with MSI and CNL tumors.
• Increasing BMI is associated with metabolically relevant alterations in 
gene expression among endometrioid endometrial carcinomas.
• Differential gene expression was related to BMI, suggesting that 
categorizing endometrial cancers into Type I/II is too simplistic.
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Figure 1. Boxplots illustrating BMI means among endometrial cancer subtypes
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Figure 2. Genomic differences between endometrial cancer tumors from obese versus non-obese 
women reveal alterations in metabolically relevant genes
Heat map representation of 181 genes found to be significantly up- or down-regulated with 
increasing BMI in endometroid histology tumors (q-value<0.01).
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Table 1
Comparison of the demographics between the endometrial cancer patients from obese and non-obese women.
Obese
(n = 185)
Non-obese
(n = 105)
p-value
Age (mean) 60.8 64.5 0.0089
Race 0.8964
White 83% 81%
Black 9% 9%
Other 8% 10%
Stage 0.2962
I 69% 78%
II 8% 5%
III 17% 15%
IV 5% 2%
Grade 0.2817
G1 30% 28%
G2 35% 28%
G3 35% 44%
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Table 2
Median overall survival of obese and non-obese women with endometrial cancer.
Number of events Median of Overall Survival
(days)
Obese 16 332.5
Non-obese 6 582.0
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